Use of amide derivative of GE 2270 factor A3 for the treatment of acne

Details for Australian Patent Application No. 2003242647 (hide)

International Classifications

Event Publications

11 September 2003 Complete Application Filed

Priority application(s): 02013268.4 17.06.02 EP

26 February 2004 Application Open to Public Inspection

Published as AU-B-2003242647

8 February 2007 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

9 August 2007 Section 223 Application Received

Vicuron Pharmaceuticals Inc. An application to extend the time from 04 Jan 2007 to 04 May 2007 in which to gain acceptance has been filed . Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000 Extensions of Time, Section 223

4 October 2007 Section 223 Application Allowed

Vicuron Pharmaceuticals Inc. The time in which to request examination has been extended to 04 May 2007. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000 Extensions of Time, Section 223

24 April 2008 Assignment before Grant

Vicuron Pharmaceuticals Inc. The application has been assigned to NAICONS S.c.a.r.l.

22 October 2009 Application Accepted

Published as AU-B-2003242647

18 February 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.